title: HIV type-1 latency: targeted induction of proviral reservoirs.
abstract: HIV type-1 (HIV-1) can establish a state of latency in infected patients, most notably in resting CD4(+) T-cells. This long-lived reservoir allows for rapid re-emergence of viraemia upon cessation of highly active antiretroviral therapy, even after extensive and seemingly effective treatment. Successful depletion of such latent reservoirs is probably essential to 'cure' HIV-1 infection and will require therapeutic agents that can specifically and efficiently act on cells harbouring latent HIV-1 provirus. The mechanisms underlying HIV-1 latency are not well characterized, and it is becoming clear that numerous factors, both cell- and virus-derived, are involved in the maintenance of proviral latency. The interplay of these various factors in the context of viral reactivation is still poorly understood. In this article, we review the current knowledge regarding the mechanisms underlying maintenance of HIV-1 latency, both transcriptional and post-transcriptional, with a focus on potential targets that might be exploited to therapeutically purge latent proviral reservoirs from infected patients.
authors.affiliation: PTC Therapeutics, Inc., South Plainfield, NJ, USA.
authors.forename: Jason D
authors.initials: JD
authors.lastname: Graci
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Colacino
authors.forename: Stuart W
authors.initials: SW
authors.lastname: Peltz
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Dougherty
authors.forename: Zhengxian
authors.initials: Z
authors.lastname: Gu
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D015195:Drug Design; D015658:HIV Infections / Q000188:drug therapy / Q000473:pathology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D014775:Virus Activation / Q000187:drug effects; D017735:Virus Latency